Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8 Baseline (Week 0) and Week 8 [clinicaltrials_resource:0000118aa46e7c26af559737dc5be2b4]Number of Participants With Overall Response (OR), as Assessed by the Investigator From the start of study treatment until 3 months after the last dose of study treatment [clinicaltrials_resource:000026652b72c8457ecae4232ef7819b]7-day point prevalence smoking abstinence verified by saliva cotinine taken post-intervention (8 weeks after baseline) [clinicaltrials_resource:00003aa5b9e3db40e06a7d66e7826d47]Antibody Concentrations Against Pneumococcal Vaccine Serotypes One month after the administration of the 3rd vaccine dose i.e. Month 5 [clinicaltrials_resource:000057dd7c420208c0b09c4fdc3fcf19]6-month Progression-free Survival 6 months after first dose [clinicaltrials_resource:000064868dd7d872c050c90eb2d4ab96]HAMD-17 total score at week 8. Tolerability. at week 8 [clinicaltrials_resource:000077b7624960148a0e79c37e613806]Persistance and adherence to treatment 2 years [clinicaltrials_resource:0000877790ab42df9b393fc0772dd1b4]Overall survival [clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45]Maximum Reading Speed Month 12 [clinicaltrials_resource:0000e5bcaaa80cc7b1f88125dca72c9a]Primary Safety Outcome as assessed by Incidence of serious adverse device effects 180 day follow-up [clinicaltrials_resource:0000f452bd285a79e2c3a23736438a7e]Treatment of clinically suspected UTI 3 weeks post-operative [clinicaltrials_resource:00017f8d5063d7e79f785ddd4b650ddc]Changes in the Edinburgh Postnatal Depression Scale (EPDS)scores from 20 weeks antenatal to 10 weeks postnatal Prenatal: 20, 28, 36weeks.Postnatal: 4 and 10 weeks [clinicaltrials_resource:0001d54261ea562ae7b516fb226d890f]Mean daily step count Change from baseline mean daily step count at 3 weeks (end of activity tracker intervention) and 5 weeks (end of texting intervention) [clinicaltrials_resource:0001de32034820ee2f457238f07c96f9]Progression of radiographic damage after one year as quantified by the van der Heijde modification of the Sharp score (SHS). Determined at baseline and after one year. 52 weeks [clinicaltrials_resource:0001e036a0dc1f1e401f37244472d6e9]Percentage of Participants reach objective response Up to 1 month [clinicaltrials_resource:0001f63a35e2c5d2c2169e7b5753252c]Total skeletal muscle mass Test Visit 1 (~ Day 13) [clinicaltrials_resource:00020f86e9dacaae71bd9224c590bdd2]Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy 2 years [clinicaltrials_resource:00021e80640d139223721e889a199de5]To determine the rate of local recurrence in patients with prostate cancer treated with radiotherapy using multiparametric prostate MR guided and standard biopsies. Completion of study [clinicaltrials_resource:00022ae05f46afb06cd2862e4f91e6f9]Blood pressure 4 weeks [clinicaltrials_resource:000233d94ca19eec7dc5c18305087ff6]Efficacy measured by the proportion of subjects in the mCRE-MITT Population at the TOC visit with a response of Success defined according to primary indication. day 12-23 (TOC visit) [clinicaltrials_resource:00024c8e82b3fd5417d62dc385d6ffa7]Confirmed tumor response as measured by RECIST criteria Up to 5 years [clinicaltrials_resource:0002564904e6e9a71837310686cbf2ac]response rate (complete and partial remissions, antileukemic effect) after four treatment courses of Decitabine, after 6 months [clinicaltrials_resource:000256a34aa461a70155e6c3b0a9414a]Mean daytime ambulatory systolic blood pressure [clinicaltrials_resource:0002648eb9864b0033c338173833f9e5]Mattis dementia rating scale [clinicaltrials_resource:00027c15ec29c76578c2f8abf1cd7ffd]Within group difference in Glucagon-like Peptide 1 secretion (evaluated by iAUC). Basline, 0, 15, 30, 45, 60, 90, 120, 180, 240 [clinicaltrials_resource:00029673dccfdf9bb84f9090ca7fa694]Relative bioavailability of GSK933776 after single dose SQ or IM administration as compared to IV infusion Blood samples will be collected at following time points: pre-dose and at (0.25, 0.5, 0.75, 1, 2, 4 hours only for IV infusion), 6, 24, 48, 72, 96, 120, 216, 336, 504, 672, 1344 and 2016 hours post dose [clinicaltrials_resource:000298a379795b2677064327fb086835]dose-limiting toxicity (DLT) of ponatinib during consolidation 1 with HDAC or IDAC 12 months [clinicaltrials_resource:0002a161db0cdb8edb446dc9d98797e0]Adverse Events That Meet Dose-limiting Toxicity Criteria Specified in Protocol. Day 4 for single-dose cohorts [clinicaltrials_resource:000315c8e833632bd80a586f6b13bad4]Number of Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Viral Load <50 Copies/mL Week 48 [clinicaltrials_resource:000344ada83e0edda440d131e9c340c1]Laser Success Measured at time of procedure [clinicaltrials_resource:00036588154d544ef353f74477e61e12]Part A: 1. The GSK256073 AUC and HDLc data in order to evolve the exposure-response (PK/PD) relationship for changes in HDLc levels Throughout eight weeks of treatment (baseline week 2, 4, 6 and 8) [clinicaltrials_resource:0003683e666584ceb49f49d793781b45]Change in whole body protein balance 2 weeks before surgery (pre-operative) and hours after the surgery (post operative) [clinicaltrials_resource:000382eadc1d621b7320becd458b706d]Dose of patient-controlled sedation/analgesia consumed During the procedure (up to 1 day) [clinicaltrials_resource:0003b2ee2fcf9db3011ff4d8ceb7d49e]Mean Change in Negative Scale Scores From the Positive and Negative Syndrome Scale (PANSS) From Baseline to Endpoint Baseline and Endpoint (Week 24 or last observation after baseline) [clinicaltrials_resource:0003deaa16de6c54334c6dc5b1357690]Pregnancy rate At performing the pregnancy test 11 days post-embryo transfer [clinicaltrials_resource:00041c4bcc8b2dd36a1d6146fed10345]Protein carbonyls levels changes in plasma day 0 and 22 [clinicaltrials_resource:000449e1ed2933ea2b3fd367cb3b55c8]Change in HbA1c (glycosylated haemoglobin) Week 0, week 30 [clinicaltrials_resource:00044e7c97791a55d3b3f82418c30ba6]spinal anesthetic success/ failure at 2 hour after the anesthetic induction [clinicaltrials_resource:00045e4b3d9ab5cf75513c6b723c5750]Neuro-mechanical efficiency of the diaphragm Artefact-free periode in the last 10 minutes of each CPAP trial [clinicaltrials_resource:0004857245f4bf4e7e4ebcad53e47e46]Number of correct movements At the end of each hand-to-mouth task. [clinicaltrials_resource:0004904ef2e6f1b453e1153d63370033]
type
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
Bio2RDF identifier
secondary-outcome
Bio2RDF namespace
clinicaltrials_vocabulary
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_vocabulary:secondary-outcome
identifier
clinicaltrials_vocabulary:secondary-outcome
title
Secondary outcome
@en
label
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
@en